228 related articles for article (PubMed ID: 38657992)
1. The evolvement of breast cancer therapies: What we have done and where all these head off.
Nurlaila I; Pambudi S
Saudi Med J; 2024 Apr; 45(4):331-340. PubMed ID: 38657992
[TBL] [Abstract][Full Text] [Related]
2. Triple-negative breast cancer: an unmet medical need.
Hudis CA; Gianni L
Oncologist; 2011; 16 Suppl 1():1-11. PubMed ID: 21278435
[TBL] [Abstract][Full Text] [Related]
3. CCL5 as a potential immunotherapeutic target in triple-negative breast cancer.
Lv D; Zhang Y; Kim HJ; Zhang L; Ma X
Cell Mol Immunol; 2013 Jul; 10(4):303-10. PubMed ID: 23376885
[TBL] [Abstract][Full Text] [Related]
4. Management of Brain and Leptomeningeal Metastases from Breast Cancer.
Pellerino A; Internò V; Mo F; Franchino F; Soffietti R; Rudà R
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198331
[TBL] [Abstract][Full Text] [Related]
5. Advances in systemic therapy for metastatic breast cancer: future perspectives.
Corona SP; Sobhani N; Ianza A; Roviello G; Mustacchi G; Bortul M; Zanconati F; Generali D
Med Oncol; 2017 Jul; 34(7):119. PubMed ID: 28526922
[TBL] [Abstract][Full Text] [Related]
6. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
[TBL] [Abstract][Full Text] [Related]
7. Triple-negative breast cancer molecular subtyping and treatment progress.
Yin L; Duan JJ; Bian XW; Yu SC
Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
[TBL] [Abstract][Full Text] [Related]
8. Triple negative breast cancer: special histological types and emerging therapeutic methods.
Cao L; Niu Y
Cancer Biol Med; 2020 May; 17(2):293-306. PubMed ID: 32587770
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers.
Lefort S; Joffre C; Kieffer Y; Givel AM; Bourachot B; Zago G; Bieche I; Dubois T; Meseure D; Vincent-Salomon A; Camonis J; Mechta-Grigoriou F
Autophagy; 2014; 10(12):2122-42. PubMed ID: 25427136
[TBL] [Abstract][Full Text] [Related]
10. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
12. Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer.
Lumachi F; Chiara GB; Foltran L; Basso SM
Cancer Genomics Proteomics; 2015; 12(6):385-90. PubMed ID: 26543084
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.
de Melo Gagliato D; Jardim DL; Marchesi MS; Hortobagyi GN
Oncotarget; 2016 Sep; 7(39):64431-64446. PubMed ID: 26824988
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapeutic options for patients with refractory breast cancer.
Fedele P; Ciccarese M; Surico G; Cinieri S
Expert Opin Pharmacother; 2019 May; 20(7):851-861. PubMed ID: 30730767
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time?
Sheridan W; Scott T; Caroline S; Yvonne Z; Vanessa B; David V; Karen G; Stephen C
Breast Cancer Res Treat; 2014 Oct; 147(3):617-29. PubMed ID: 25209005
[TBL] [Abstract][Full Text] [Related]
16. [Breast cancer with triple-negative phenotype in the Russian patient population. Clinical and morphologic features].
Zhukova LG
Vopr Onkol; 2015; 61(2):189-94. PubMed ID: 26087596
[TBL] [Abstract][Full Text] [Related]
17. What is triple-negative breast cancer?
Irvin WJ; Carey LA
Eur J Cancer; 2008 Dec; 44(18):2799-805. PubMed ID: 19008097
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Factors and Survival According to Tumor Subtype in Women With Breast Cancer Brain Metastases.
Lopes S; Vieira I; Abreu M; Pousa I; Ferreira A; Sousa S; Pereira D
Curr Probl Cancer; 2022 Dec; 46(6):100866. PubMed ID: 36179388
[TBL] [Abstract][Full Text] [Related]
19. Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises.
Garmpis N; Damaskos C; Garmpi A; Kalampokas E; Kalampokas T; Spartalis E; Daskalopoulou A; Valsami S; Kontos M; Nonni A; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
Cancer Genomics Proteomics; 2017; 14(5):299-313. PubMed ID: 28870998
[TBL] [Abstract][Full Text] [Related]
20. Recent Progress in Triple Negative Breast Cancer Research.
Mouh FZ; Mzibri ME; Slaoui M; Amrani M
Asian Pac J Cancer Prev; 2016; 17(4):1595-608. PubMed ID: 27221827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]